| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 01/06/2004 | US6673837 Acetyl L-carnitine salt with a dicarboxylic organic acid and process for preparing same |
| 01/06/2004 | US6673810 Anticoagulants |
| 01/06/2004 | US6673803 Quinazoline derivatives and pharmaceutical compositions containing them |
| 01/06/2004 | US6673798 PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same |
| 01/06/2004 | US6673795 Pyrimidine, pyrazine and triazane derivatives |
| 01/06/2004 | US6673794 Substituted aminomethyl-phenyl-cyclohexane derivatives |
| 01/06/2004 | US6673780 Such as 4-(4-(3-hydroxy-3-methyl-butane-1-sulfinylmethyl)-phenylmethanesulfinyl)-2 -methyl-butan1-ol for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders |
| 01/06/2004 | US6673768 Transgenic animal models for cardiac hypertrophy and methods of use thereof (treating) |
| 01/06/2004 | US6673604 Muscle cells and their use in cardiac repair |
| 01/06/2004 | US6673564 Detecting modulators of polypeptide activity in cell; obtain cell, incubate with modulator, monitor cellular activity and compare to control |
| 01/06/2004 | US6673555 Methods of using SCAP antagonists |
| 01/06/2004 | US6673543 Joining liver receptors to solid support; generate solid support, join aniline derivative to support, incubate with aldehye, ketone, incubate aniline derivative with acylating agent, recover support |
| 01/06/2004 | US6673379 Use of non-alkalized cocoa solids in a drink |
| 01/06/2004 | US6673377 Extracts derived from Pueraria mirifica, Butea superba and/or Mucuna collettii and extraction thereof |
| 01/06/2004 | CA2301990C New substitute dimerized derivatives, process for preparing them, and pharmaceutical compounds containing them |
| 01/06/2004 | CA2253870C Inhibition of matrix metalloproteases by substituted phenalkyl compounds |
| 01/06/2004 | CA2145248C Pharmaceutical compositions containing time-released orally taken trimetazidine |
| 01/06/2004 | CA2135083C Antibodies to p-selectin and their uses |
| 01/02/2004 | EP1375663A1 Novel protein, dna thereof and use of the same |
| 01/02/2004 | EP1375662A1 A novel polypeptide compose substance for promoting blood and blood vessel cell growth |
| 01/02/2004 | EP1375516A2 Method of production of a recombinant polypeptide of the LSR receptor |
| 01/02/2004 | EP1375496A1 N-aryl-substituted cyclic amine derivative and medicine containing the same as active ingredient |
| 01/02/2004 | EP1375482A1 Benzamidine derivative |
| 01/02/2004 | EP1374912A1 Use of metaloporphyrins for treatment of arteriosclerotic lesions |
| 01/02/2004 | EP1374896A1 Blood rheology improving agents |
| 01/02/2004 | EP1374889A1 Method of inducing angiogenesis by micro-organs |
| 01/02/2004 | EP1374885A1 Use of at least one peptide of alpha-s2 casein with inhibiting activity of ACE for the preparation of medicaments and foodstuffs |
| 01/02/2004 | EP1374883A1 Nasal spray containing a plant extract for the treatment of diseases such as herpes zoster, hematoma, mastitis and cardiovasculatory weakness |
| 01/02/2004 | EP1374868A1 Remedies and/or preventives for diabetic ischemic heart diseases |
| 01/02/2004 | EP1374865A1 Use of R,S-(+/-)-alpha-lipoic acid, R(+)-alpha-lipoic acid or S-(-)-alpha-lipoic acid in reduced or oxidised form, or their metabolites as well as their salts, esters or amides, for the treatment of hearing disorders |
| 01/02/2004 | EP1374862A2 Use of a substance influencing the degree of phosphorylation of BAD for the treatment of atherosclerosis |
| 01/02/2004 | EP1373517A2 Human kinases |
| 01/02/2004 | EP1373503A2 Neurotrophic factors |
| 01/02/2004 | EP1373489A2 Human dual specificity protein phosphatase 7-like protein |
| 01/02/2004 | EP1373485A2 Ikk2 variant, dino gene, lectin-like receptor gene, and proteins encoded thereby |
| 01/02/2004 | EP1373475A2 Immunotherapy based on dendritic cells |
| 01/02/2004 | EP1373319A2 Composition comprising il-22 inhibitors and use thereof for treating inflammatory disorders |
| 01/02/2004 | EP1373317A2 Nuclear hormone receptor ligand binding domains |
| 01/02/2004 | EP1373316A2 Nuclear hormone receptor ligand binding domain |
| 01/02/2004 | EP1373315A2 Nuclear hormone receptor ligand binding domain |
| 01/02/2004 | EP1373313A2 Proteins and nucleic acids encoding same |
| 01/02/2004 | EP1373306A2 Cytoskeletion-associated proteins |
| 01/02/2004 | EP1373287A1 Process for obtaining lignan, pharmaceutical compositions and uses thereof |
| 01/02/2004 | EP1373269A1 Jun kinase inhibitors |
| 01/02/2004 | EP1373265A1 Substituted 2,6-diamino-3,5-dicyano-4-aryl-pyridines and their use as adenosine receptor-selective ligands |
| 01/02/2004 | EP1373263A1 Heterocyclic compounds for aging-related and diabetic vascular complications |
| 01/02/2004 | EP1373262A2 Azacycloalkyl substituted acetic acid derivatives for use as mmp inhibitors |
| 01/02/2004 | EP1373259A1 Pyridazinone aldose reductase inhibitors |
| 01/02/2004 | EP1373257A1 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| 01/02/2004 | EP1373251A2 Non-imidazole compounds as histamine h3 antagonists |
| 01/02/2004 | EP1373249A1 Imidazolidine derivatives, their preparation, and their use as antinflamatory agent |
| 01/02/2004 | EP1373242A1 Dimeric isoflavones |
| 01/02/2004 | EP1373240A2 Retinoid x receptor modulators |
| 01/02/2004 | EP1373233A1 Derivatives of n-(arylsulfonyl)beta-aminoacids comprising a substituted aminomethyl group, the preparation method thereof and the pharmaceutical compositions containing same |
| 01/02/2004 | EP1373223A1 Cyano-substituted dihydropyrimidine compounds and their use to treat diseases |
| 01/02/2004 | EP1373221A2 Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases |
| 01/02/2004 | EP1373220A1 Benzimidazoles that are useful in treating sexual dysfunction |
| 01/02/2004 | EP1373219A1 Thiohydantoins and use thereof for treating diabetes |
| 01/02/2004 | EP1373217A1 2-mercapto-4,5-diarylimidazole derivatives and the use thereof as cyclooxygenase inhibitors |
| 01/02/2004 | EP1373216A1 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
| 01/02/2004 | EP1373207A1 Novel amlodipine camsylate and method for preparing thereof |
| 01/02/2004 | EP1373205A1 Novel piperidine derivatives as modulators of chemokine receptors |
| 01/02/2004 | EP1373204A2 Heterocyclic compounds |
| 01/02/2004 | EP1373203A1 Cyclopropylindole derivatives as selective serotonin reuptake inhibitors |
| 01/02/2004 | EP1373191A1 Acylated indanyl amines and their use as pharmaceuticals |
| 01/02/2004 | EP1373185A2 Hydrophobic polyamine analogs and methods for their use |
| 01/02/2004 | EP1373182A1 Conjugated unsaturated glyceride mixtures and a method for producing the same |
| 01/02/2004 | EP1372737A2 Preparation for the prophylaxis of restenosis |
| 01/02/2004 | EP1372735A2 Conjugate of hydroxyalkyl starch and an active agent |
| 01/02/2004 | EP1372724A2 Use of immunoregulatory antibodies in the treatment of neoplastic disorders |
| 01/02/2004 | EP1372702A1 Method of treatment of hypoxia/ischaemia related blood flow resistance |
| 01/02/2004 | EP1372695A2 Cell damage inhibitor |
| 01/02/2004 | EP1372689A2 Use of ikk-beta inhibitors and method for discovery of said inhibitors |
| 01/02/2004 | EP1372688A2 Somatostatin antagonists |
| 01/02/2004 | EP1372681A1 Biologically active chloroform fraction of an extract obtained from a mangrove plant salvadora persica l |
| 01/02/2004 | EP1372664A1 Use of certain steroids for treatment of blood cell deficiencies |
| 01/02/2004 | EP1372657A2 A method of treating proliferative diseases using eg5 inhibitors |
| 01/02/2004 | EP1372656A1 Pyrazolo[4,3-d]pyrimidinone compounds as cgmp pde inhibitors |
| 01/02/2004 | EP1372648A2 Tie2 receptor kinase inhibitors for treating angiogenic diseases |
| 01/02/2004 | EP1372647A2 Use of substituted imidazo 1,2-a]-pyridine compounds as medicaments |
| 01/02/2004 | EP1372644A2 Use of substituted imidazo 1,2-a]-pyridine-3-yl-amide and imidazo 1,2-a]-pyridine-3-yl-amine compounds as medicaments |
| 01/02/2004 | EP1372637A2 Premixed amiodarone parenteral solution and method for making the same |
| 01/02/2004 | EP1372634A2 Fumaric acid amides |
| 01/02/2004 | EP1372632A1 Proliferative activator receptor (ppar) compounds |
| 01/02/2004 | EP1372629A2 Therapeutic treatment |
| 01/02/2004 | EP1372627A1 Use of breakers of advanced glycation endproducts for treating deleterious effects of aging and debilitating diseases |
| 01/02/2004 | EP1372626A1 Compositions and methods for enhancing drug delivery across and into ocular tissues |
| 01/02/2004 | EP1372616A2 A stable pharmaceutical composition of pravastatin |
| 01/02/2004 | EP1372529A2 Methods and apparatus for stenting comprising enhanced embolic protection, coupled with improved protection against restenosis and thrombus formation |
| 01/02/2004 | EP1372412A2 Composition improving age-related physiological deficits and increasing longevity |
| 01/02/2004 | EP1036062B1 Hydroxamic acid derivatives as matrix metalloprotease (mmp) inhibitors |
| 01/01/2004 | US20040002608 Central nervous system disorders |
| 01/01/2004 | US20040002540 Method for increasing the concentration of ascorbic acid in brain tissues of a subject |
| 01/01/2004 | US20040002539 Enzyme inhibitors; anticoagulants; blood collecting device |
| 01/01/2004 | US20040002533 Culture product of Streptomyces; lanosterol synthase inhibitor; anticholesterol agents, fungicides |
| 01/01/2004 | US20040002530 Composition for the prevention and/or treatment in newborn babies of the effects of complications during childbirth |
| 01/01/2004 | US20040002529 Mixture with diuretics; hypotensive agents |
| 01/01/2004 | US20040002525 Obesity; osteoporosis |
| 01/01/2004 | US20040002524 Cardiovascular disorders; osteoporosis; central nervous system disorders |
| 01/01/2004 | US20040002523 Aryl substituted pyrazoles, triazoles and tetrazoles, and the use thereof |